Detalles de la búsqueda
1.
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
N Engl J Med
; 384(14): 1289-1300, 2021 04 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33616314
2.
Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study.
Acta Oncol
; 61(1): 52-57, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34736367
3.
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.
N Engl J Med
; 379(5): 417-427, 2018 Aug 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29860937
4.
Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Invest New Drugs
; 39(6): 1641-1648, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34322775
5.
Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.
Lancet Oncol
; 21(9): 1173-1187, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32758455
6.
Long survival of patients with metastatic clear cell renal cell carcinoma. Results of real life study of 344 patients.
Int J Cancer
; 146(6): 1643-1651, 2020 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31318983
7.
A prospective observational study on the evaluation of everolimus-related adverse events in metastatic renal cell carcinoma after first-line anti-vascular endothelial growth factor therapy: the AFINITE study in France.
Support Care Cancer
; 25(7): 2055-2062, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28188447
8.
Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib.
BJU Int
; 118(6): 890-901, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27417418
9.
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Lancet Oncol
; 16(7): 787-94, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26028518
10.
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.
Lancet Oncol
; 16(1): 76-86, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25498218
11.
Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer.
BJU Int
; 115(5): 744-52, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24947139
12.
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Lancet Oncol
; 15(13): 1442-1450, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25456363
13.
An international phase 3 trial in head and neck cancer: quality of life and symptom results: EORTC 24954 on behalf of the EORTC Head and Neck and the EORTC Radiation Oncology Group.
Cancer
; 120(3): 390-8, 2014 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24452673
14.
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 14(2): 149-58, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23306100
15.
Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study.
Eur J Cancer
; 201: 113589, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38382153
16.
PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort.
Eur J Cancer
; 205: 114121, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38749111
17.
Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial.
Lancet Healthy Longev
; 5(6): e392-e405, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38759667
18.
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.
Oncoimmunology
; 13(1): 2290787, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38170160
19.
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.
Oncologist
; 18(11): 1190-1, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-24105751
20.
Geriatric Assessment Implementation before Chemotherapy in MEtastatic Prostate Cancer, Results from the Real-Life Study GAMERS.
J Clin Med
; 12(4)2023 Feb 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36836171